Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88858 | 0.80 | CA12 (0.45) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29398807 | 0.80 | CA12 (0.45) | CA12CA1CA2CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9756819 | 0.78 | CA12 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL28201382 | 0.78 | CA12 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| Acetic Acid SCHEMBL6200962 | 0.74 | CA12 (0.38) | CA12CA1CA2CA9ALDH1A1 | |
| Isobutane SCHEMBL9756824 | 0.73 | CA12 (0.40) | CA12CA1CA2CA9ALDH1A1 | |
| Oxazole SCHEMBL4863479 | 0.68 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL10860629 | 0.66 | GPR3 (0.41) | CA12CA1CA2CA9GPR3 | |
| SCHEMBL20529330 | 0.65 | CA2 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL5613160 | 0.65 | CA12 (0.40) | CA12CA1CA2CA9GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266457-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250281482-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250282808-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12350267-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4464376-A2 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | Mirum Pharmaceuticals, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12145959-B2 | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4424363-A2 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | Mirum Pharmaceuticals, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4137137-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11497745-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220265649-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-11376251-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220152022-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220133738-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220105092-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114096268-A | Methods for increasing growth in pediatric subjects with cholestatic liver disease | 米鲁姆制药公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114072153-A | Methods for treating cholestasis | 米鲁姆制药公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281482-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | CA12 2489/4885CA1 3579/4885CA2 1660/4885 |
| US-20240189308-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | CA12 504/4885CA1 730/4885CA2 355/4885 |
| US-12145959-B2 | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease | SLC10A1, SLC10A2, ABCB11 | CA12 1741/4885CA1 2379/4885CA2 794/4885 |
| US-20250360127-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | CA12 504/4885CA1 730/4885CA2 355/4885 |
| US-11376251-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SLC10A1, SLC10A2, ABCB11 | CA12 2489/4885CA1 3579/4885CA2 1660/4885 |
| US-12350267-B2 | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | SLC10A1, SLC10A2, ABCB11 | CA12 2489/4885CA1 3579/4885CA2 1660/4885 |
| US-20250282808-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | CA12 1741/4885CA1 2379/4885CA2 794/4885 |
| US-20220105092-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | CA12 504/4885CA1 730/4885CA2 355/4885 |
| US-20220152022-A1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, FABP1 | CA12 803/4885CA1 2378/4885CA2 1806/4885 |
| US-20220265649-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | CA12 2489/4885CA1 3579/4885CA2 1660/4885 |
| US-20220133738-A1 | GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY | SLC10A1, ABCB11, SLC10A2 | CA12 3882/4885CA1 4297/4885CA2 2861/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | CA12 1023/4885CA1 1263/4885CA2 304/4885 |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | CA12 504/4885CA1 730/4885CA2 355/4885 |
| US-11497745-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, NR1H4 | CA12 504/4885CA1 730/4885CA2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.